investigated the efficacy and safety of the antimuscarinic tolterodine extended release (ER), the α 1-receptor antagonist tamsulosin, and a combination of both, in men with overactive bladder and ...
The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.
Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...
HealthDay on MSN17d
FDA Approves Gemtesa for Overactive Bladder in Men With BPHGemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback